Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Concert

“Well suited for everything from bluesy porch pickin’ to speakeasy swingin’”: Gretsch drops two limited edition Jim Dandy parlour and concert acoustics with solid spruce tops and off-the-charts vintage mojo

They're small-bodied, budget-friendly, inspired by ye olde Rex catalogue pre-War models... Get 'em while they're hot, people

MusicRadar

Gretsch glow-up: One of our favorite parlor guitars just got a limited-edition makeover – and at $249, it’s still irresistibly affordable

The Jim Dandy has been given an ornate new finish and an updated spec sheet, making it more desirable than ever before

Guitar World

Exclusive: Israeli documents show expansive government effort to shape US discourse around Gaza war

As the Gaza war rages, Israeli funds target US college campuses and push to redefine antisemitism in US law

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Benzinga

The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial. Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)…

Benzinga

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

US Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.